ARWR Stock Ownership Breakdown

A company's 13F filings with the Securities and Exchange Commission (SEC) provides investors with comprehensive information about institutional ownership in a listed company, a sign of strength in terms of how many institutions have confidence in that company. The number of institutional investors who currently own ARWR shares is 373, representing 79.71% of the company's common stock.

LEGAL & GENERAL GROUP PLC, in the last quarter, reduced its stake in ARWR by -0.58% restricting it's holding to 274.05 thousand shares of worth nearly $7.84M. NUVEEN ASSET MANAGEMENT, LLC also lessened -4.78% of the ARWR shares from its portfolio, reducing its holding to 328.03 thousand shares of worth $9.38M. SCHONFELD STRATEGIC ADVISORS LLC also shunned ARWR shares holding by -9.67% last quarter which brought its holding to 415.78 thousand shares worth $11.89M.

As per its latest 13F filing, CITIGROUP INC increased its stake in ARWR by 50.31% in the last quarter. The institutional holder raised its holding to 280.98 thousand shares having worth more than $8.04M. MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. also added 67.25% more shares of ARWR to its portfolio, raising its holding to 327.78 thousand shares of worth $8.00M. RHUMBLINE ADVISERS also increased its ARWR shares holding by 15.43% which brought its holding to 372.11 thousand shares worth $10.64M.

The insider with the most stakes in ARWR is Anzalone Christopher Richard , Chief Executive Officer at the company. Additionally, ARWR stock is highly held by COO and General Counsel O'Brien Patrick and Chief Financial Officer Myszkowski Kenneth Allen among others.

Company executives, directors, and other insiders own 4.47% percent of Arrowhead Pharmaceuticals, Inc.'s stock. Within the last six months, there have been 14 transaction(s) in which ARWR insiders have sold stock, totaling 102.67K shares. Insiders that have sold shares include O'BRIEN PATRICK, MYSZKOWSKI KENNETH ALLEN, and HAMILTON JAMES C.

There have been 0 transaction(s) during the past 6-months in which Arrowhead Pharmaceuticals, Inc. insiders have bought stock, totalling 0 shares

Around 13.88M Arrowhead Pharmaceuticals, Inc. shares are held by insiders, which represents about 4.47% of ARWR stock.

ARWR Chief Executive Officer, Anzalone Christopher Richard holds the largest portfolio of the company's shares. ARWR shares owned by Anzalone total nearly 3.76 million.

LEGAL & GENERAL GROUP PLC is the largest institutional owner in ARWR which holds 274.05 thousand shares worth $7.84M or 0.22% of the total ARWR shares outstanding followed by CITIGROUP INC with ownership of 280.98 thousand shares representing 0.26% of the ARWR ownership. MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. is the third largest stakeholder with 327.78 thousand shares or 0.27% of the ownership worth more than $8.00M.

Stock options give the owner the ability but not the obligation to buy or sell a security at a predetermined price and date. Stock options can be classified into two types: puts and calls. A put is a bet on falling stock, and a call is a bet on rising stock. As far as the ARWR is concerned, it is a stock which is optionable.

Number of ARWR shares short is 9.45M. Shares short is a market sentiment in which investors have sold their shares short in a given stock but have not yet covered them or closed them out.

As of today, 124.43M shares of ARWR are outstanding.

Float represents the number of tradeable shares in a specific stock. By subtracting restricted and closely-held shares from a firm's total outstanding shares, we can calculate its floating stock. The term "closely-held shares" refers to shares held by employees, major shareholders, and company insiders. At present, ARWR has 110.49M shares in float.

Short ratio is calculated by dividing the number of short shares, short interest or bets that shareholders will sell short from the average daily volume. A higher ratio indicates longer times needed to repurchase borrowed shares (sold). The short ratio for ARWR is 8.94.